SAN DIEGO, November 4, 2016 – ViaCyte, Inc., a privately-held regenerative medicine company, today announced two presentations at upcoming healthcare events. ViaCyte is advancing two novel cell replacement therapies as potential long-term type 1 diabetes treatments. The Company’s potential breakthrough treatment for high-risk type 1 diabetes, called PEC-DirectTM is expected to begin clinical trials early next year. ViaCyte’s PEC-EncapTM (also known as VC-01TM) product candidate is the first pluripotent stem cell-derived islet cell replacement therapy for the treatment of type 1 diabetes in clinical-stage development.
Details of the presentations are as follows:
Event: Institute for Regenerative Medicine & Bioengineering Symposium: Engineering Cells and Tissues to Scale
Speaker: Dr. Allan Robins, Senior Vice President, Science and Technology
Date/Time: November 7, 1:50 PM EST
Location: Smilow Auditorium, University of Pennsylvania, Philadelphia
Event: 2nd Cleveland Clinic Beta Cell Therapy Symposium on Diabetes: Advances in Management of Diabetes
Speaker: Dr. Evert Kroon, Senior Director, Research Physiology
Date/Time: November 11, 3:45 PM EST
Location: Cleveland Clinic Administrative Campus, Beachwood, Ohio
For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on the derivation of pancreatic progenitor cells, which are then implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte has two products in development. The PEC-Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients that have severe hypoglycemic episodes, extreme glycemic lability, and/or impaired hypoglycemia awareness. The PEC-Encap (formerly VC-01) product candidate delivers pancreatic progenitor cells in an immunoprotective device and is currently being evaluated in a Phase 1/2 trial in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.